Combined Modality Therapy of Central Nervous System Tumors

The American Cancer Society anticipates that 16,500 patients will be diagnosed with primary malignant tumors of the central nervous system in 2000, with about 200,000 individuals presenting with brain metastases.

The advances in the treatment of solid tumors have contributed significantly to the major increase in metastatic cancers to the brain.

Of the primary malignant tumors of the brain, more than 50% are high-grade gliomas; the incidence has been increasing among older patients over the past decade.

Major developments in new technologies in the treatment of primary brain tumors as well as metastatic disease are covered in depth.

Even though management is difficult, advances are being made.

This book is a concerted effort to present data regarding basic science research efforts alongside their translation into clinical practice using combined, integrated multimodal programs of treatment.

Progress has been made, but innovatice approaches need to be pursued.